Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma.
- Author:
Li-tao XU
1
;
Zhen CHEN
;
Jun-hua LIN
;
Zhen-hua ZHOU
;
Hao CHEN
;
Zhi-qiang MENG
;
Lu-ming LIU
Author Information
- Publication Type:Clinical Trial
- MeSH: Adolescent; Adult; Aged; Antineoplastic Agents; adverse effects; therapeutic use; Benzenesulfonates; adverse effects; therapeutic use; Carcinoma, Hepatocellular; pathology; therapy; Chemoembolization, Therapeutic; adverse effects; Combined Modality Therapy; Diarrhea; etiology; Disease Progression; Doxorubicin; administration & dosage; adverse effects; analogs & derivatives; Female; Follow-Up Studies; Humans; Liver Neoplasms; pathology; therapy; Male; Middle Aged; Neoplasm Staging; Niacinamide; analogs & derivatives; Organoplatinum Compounds; administration & dosage; adverse effects; Phenylurea Compounds; Pyridines; adverse effects; therapeutic use; Remission Induction; Survival Rate; Thrombocytopenia; etiology; Young Adult
- From: Chinese Journal of Oncology 2010;32(9):703-705
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the efficacy and side effects of transarterial chemoembolization (TACE) combined with sorafenib for advanced hepatocellular carcinoma (HCC).
METHODSForty patients with HCC were treated with sorafenib (400 mg bid) after TACE. The efficacy was evaluated according to RECIST 1.1 criteria, and side effects were assessed by NCI CTC 3.0 criteria.
RESULTSAmong the forty cases, one case achieved complete remission (CR), seven cases achieved partial remission (PR), nineteen cases achieved stable disease (SD) and thirteen cases had progressive disease (PD). The disease control rate (DCR) was 67.5%. The overall survival time was 1 - 18 months, and 1-year survival rate was 54.0%. The major adverse events were hand-foot skin reaction, diarrhea and thrombocytopenia.
CONCLUSIONThe combined therapy of TACE and sorafenib is effective and well tolerated for advanced HCC.
